Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report
0
Authors
Donato Cosi
Donato Cosi•Cristina Fragale•Luana Calabrò
Published
July 9, 2024
Abstract
Third-generation tyrosine kinase inhibitors are the first-line gold standard in treating advanced non-small-cell lung cancer bearing common